Recently, we have reported that two secreted proteoglycans, proline/arginine-rich end and leucine-rich protein (PRELP) and osteomodulin (OMD) function as inhibitors of bladder cancer initiation by inhibiting epithelial-mesenchymal transition (EMT) and by activating cell-cell adhesion of bladder epithelial cells (Papadaki et al., 2020). Here, PRELP is linked to urinary bladder carcinoma.